title: Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice.
abstract: The mechanisms underlying phenacetin-induced toxicity and carcinogenicity are not clear. In particular, it is not known whether these effects are mediated by metabolic activation of the drug. CYP1A2 is known to metabolize phenacetin in vitro. To determine the role of this enzyme in vivo, the toxicity and carcinogenicity of phenacetin was examined in Cyp1a2-null mice (that lack CYP1A2). Six- to 8-week-old wild type (+/+) or null (-/-) mice were fed either a control diet, or one containing 1.25% phenacetin, ad libitum for up to 67 weeks. Representative groups of mice were examined for phenacetin-induced toxicity and carcinogenicity after 36, 48, 58, or 67 weeks of feeding. Consistent with the known role of CYP1A2 in phenacetin metabolism, plasma levels of phenacetin were higher and acetaminophen levels lower in the (-/-) mice fed phenacetin compared to phenacetin-fed (+/+) controls. Weight gain was significantly depressed in both groups of phenacetin-fed mice after 4 weeks of feeding, and continued to be lower for the remainder of the experiment, compared to controls. Hepatomegaly and splenomegaly were more severe in (-/-) mice but present in both genotypes fed phenacetin at all time points assessed. Histological analysis of liver, kidney, spleen, and urogenital tract also revealed a differential response in the (-/-) mice fed phenacetin compared to (+/+) mice fed the same diet. Further, mortality was the most severe in the (-/-) mice fed phenacetin than in all other groups. Despite significant toxicity in (-/-) mice fed phenacetin, only one renal carcinoma was found among them. Results from this work demonstrate that, in the absence of CYP1A2, phenacetin is more toxic than in controls. This provides evidence that metabolism of phenacetin by CYP1A2 alters toxicity in vivo, and suggests that alternate CYP1A2-independent metabolic pathways contribute to its toxicity.
authors.affiliation: Laboratory of Metabolism, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. jpeters@helix.nih.gov
authors.forename: J M
authors.initials: JM
authors.lastname: Peters
authors.forename: H
authors.initials: H
authors.lastname: Morishima
authors.forename: J M
authors.initials: JM
authors.lastname: Ward
authors.forename: C J
authors.initials: CJ
authors.lastname: Coakley
authors.forename: S
authors.initials: S
authors.lastname: Kimura
authors.forename: F J
authors.initials: FJ
authors.lastname: Gonzalez
mesh_terms: D000082:Acetaminophen / Q000097:blood / Q000633:toxicity*; D000818:Animals; D002273:Carcinogens / Q000633:toxicity*; D002277:Carcinoma / Q000139:chemically induced; D019388:Cytochrome P-450 CYP1A2 / Q000502:physiology*; D005260:Female; D007680:Kidney Neoplasms / Q000139:chemically induced; D008297:Male; D051379:Mice; D009929:Organ Size / Q000187:drug effects; D010615:Phenacetin / Q000008:administration & dosage / Q000097:blood / Q000633:toxicity*; D015996:Survival Rate; D013997:Time Factors; D001743:Urinary Bladder / Q000187:drug effects / Q000473:pathology
chemical_list: D002273:Carcinogens; D000082:Acetaminophen; D019388:Cytochrome P-450 CYP1A2; D010615:Phenacetin